Press release 2020-12-07

Biotech AB makes changes in leadership to strengthen growth

Biotech AB has appointed Dr Fritiof Pontén as new CEO and Anders Grahn as working Chairman of the Board of Directors. This strategic re-organisation will further strengthen the company’s position as an internationally well recognized distributor within the life science industry.

Dr Pontén has a PhD in organic chemistry and 17 years experience from AstraZeneca where he was working with drug development from very early to IND phase including process and technology development. Before he joined Biotech AB as R&D Manager in 2018 he was CEO of the biopharmaceutical company QureTech Bio AB in Umeå, Sweden.

Beside the responsibility as Chairman Anders Grahn will now focus his work on sales and business development. Under his leadership Biotech AB has developed to be an established and leading supplier within the life science industry. Mr Grahn has been CEO since he in 2007 co-founded the company, together with the serial entrepreneur Ralf Jutvik.

”This is perfect timing for the next step in the growth of Biotech AB that will enable us to reach new markets with established and new products”, says Ralf Jutvik.

Fritiof Pontén comments: ”Biotech AB has a dedicated team and an exciting role in providing great fluidic solutions to instrument manufactures and distributors. I see many new opportunities to bring innovative products to these customers”

Contacts

Fritiof Pontén    CEO

E-mail/Phone:   fritiof.ponten@biotechfluidics.com         +46 722 119 101

Anders Grahn    Chairman of the Board of Directors

E-mail/Phone:   anders.grahn@biotechfluidics.com         +46 702 444 644

About Biotech AB

Biotech AB supplies great fluidic components to manufacturers of advanced scientific instrumentation & distributors around the world. Biotech AB is the Global Premium Distributor of IDEX Health & Science, and have offices in Europe, US and Japan. Biotech AB help our customers eliminate troubles with bubbles with our customized degassing solutions. The Biotech group had 2019 a turnover of around 7 MUSD.